TSC is a rare genetic disorder affecting about one million people globally, and Afinitor is the only approved non-surgical option indicated to treat non-cancerous brain and kidney tumours
Late in 2015, the company closed on a $50m Series A round, and completed its $100m Series B round this week. The most recent round was led by
The alliance will evaluate the potential for combining Astex’s guadecitabine (SGI-110) small molecule DNA hypomethylating agent with Genentech’s atezolizumab investigational anti-PD-L1 monoclonal antibody. The safety and pharmacology of
Ibrance is an oral inhibitor of CDKs 4 and 6, which are important regulators of the cell cycle that trigger cellular progression. The study met its primary endpoint
The companies will target several G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. The deal will see Heptares apply its StaR platform for the creation of
Labeling negotiations are now underway. The FDA extended the original action date of 17 January twice to enable for complete review. Sustol’s long-acting formulation is based on Heron’s
The designation was based on data from the ongoing Phase Ib Keynote-013 and Phase II Keynote-087 studies evaluating the drug as a single agent in patients with cHL,
The recommendations were based on the review of data from 25 clinical studies undertaken in 15 different endemic and non-endemic countries across the world. More than 40,000 volunteers
Under the recommendation, Translarna would be made available as part of a confidential financial agreement between NHS England and PTC. The regulator noted that PTC should an acceptable
Gilotrif was initially approved in the US in July 2013 to treat epidermal growth factor receptor (EGFR)-positive metastatic non-small cell lung cancer (NSCLC). It has now been approved
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.